A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

Phase 1b: Overall Response (OR)

Overall response is defined as a PR or CR at any point between the time of prizlo-cel infusion until PD or start of subsequent anti-lymphoma therapy, whichever occurs first (per Lugano 2014 guidelines).

Time frame: Up to 2 Years post prizlo-cel infusion

Phase 1b: Duration of Response (DOR)

DOR is defined as the time from the first documented CR or PR after prizlo-cel infusion until PD or death, whichever occurs first (per Lugano 2014 guidelines).

Time frame: Up to 2 Years post prizlo-cel infusion

Phase 1b: Pharmacokinetic Evaluation of Prizlo-Cel

Prizlo-cel blood levels will be reported.

Time frame: Up to 2 Years post prizlo-cel infusion

Phase 2: Occurrence of Adverse Events (AEs) by Severity

Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 as follows: Grade 1 (Mild), Grade 2 (Moderate), Grade 3 (Severe), Grade 4 (Life-threatening ), Grade 5 (Death). Cytokine release syndrome (CRS), Immune effector cell-associated neurotoxicity syndrome (ICANS), and Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) will be graded according to the American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading.

Time frame: Up to 2 Years post prizlo-cel infusion

Phase 2: Complete Response (CR)

A CR is defined as at any point between the date of prizlo-cel infusion until PD or start of subsequent anti-lymphoma therapy, whichever occurs first.

Time frame: Up to 2 Years post prizlo-cel infusion

Phase 2: Duration of Response (DOR)

DOR is defined as the time from the first documented CR or PR after prizlo-cel infusion to relapse or death, whichever occurs first.

Time frame: Up to 2 Years post prizlo-cel infusion

Phase 2: Progression Free Survival (PFS)

PFS is defined as the time from the date of prizlo-cel infusion to the date of first documented disease progression, or death due to any cause, whichever occurs first.

Time frame: Up to 2 Years post prizlo-cel infusion

Phase 2: Overall Survival (OS)

OS is defined as the time from the date of prizlo-cel infusion to the date of death due to any cause.

Time frame: Up to 2 Years post prizlo-cel infusion

Phase 2: Maximum Observed Blood Concentration (Cmax) for Prizlo-Cel

Blood samples will be analyzed to report Cmax for prizlo-cel.

Time frame: Up to 2 Years post prizlo-cel infusion

Phase 2: Time to Reach Maximum Observed Cmax (Tmax) for Prizlo-Cel

Blood samples will be analyzed to report Tmax for prizlo-cel.

Time frame: Up to 2 Years post prizlo-cel infusion

Phase 2: Area Under the Blood Concentration Time Curve (AUC) for Prizlo-Cel

AUC for prizlo-cel will be reported.

Time frame: Up to 2 Years post prizlo-cel infusion

Change From Baseline of the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Symptom Score

The FACT-Lym was developed for adult patients with lymphoma. The FACT Lym is self-administered, with a recall period for all items being the past 7 days. Responses are rated on a 5-point Likert response scale ranging from 0 "not at all" to 4 "very much". Higher scores indicate fewer symptoms and better well-being.

Time frame: From Baseline Up to 18 months